OBJECTIVE: To investigate methods of fertility preservation in younger women exposed to adjuvant chemotherapy for breast cancer. DESIGN: Systematic review of literature. SETTING: Academic Department of Medical Oncology. PATIENT(S): Premenopausal women exposed to adjuvant chemotherapy for breast cancer. MAIN OUTCOME MEASURE(S): Fertility preservation. RESULT(S): Data for fertility preservation in this setting come from nonrandomized trials and observational studies. The main methods of fertility preservation are ovarian protection by gonadotropin-releasing hormone (GnRH) agonists, cryopreservation of embryos after in vitro fertilization, and preservation of operatively sampled ovarian tissue or eggs after stimulation and puncture. Ongoing trials are assessing the role of ovarian protection by GnRH agonists. CONCLUSION(S): At present, there are no high-level, evidence-based recommendations for preservation of fertility or of ovarian function in women with breast cancer. This is an important issue for young breast cancer survivors, and further studies are needed. Moreover, the interplay between ovarian protection by GnRH agonists and the efficacy of adjuvant chemotherapy remains elusive. Copyright (c) 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.
OBJECTIVE: To investigate methods of fertility preservation in younger women exposed to adjuvant chemotherapy for breast cancer. DESIGN: Systematic review of literature. SETTING: Academic Department of Medical Oncology. PATIENT(S): Premenopausal women exposed to adjuvant chemotherapy for breast cancer. MAIN OUTCOME MEASURE(S): Fertility preservation. RESULT(S): Data for fertility preservation in this setting come from nonrandomized trials and observational studies. The main methods of fertility preservation are ovarian protection by gonadotropin-releasing hormone (GnRH) agonists, cryopreservation of embryos after in vitro fertilization, and preservation of operatively sampled ovarian tissue or eggs after stimulation and puncture. Ongoing trials are assessing the role of ovarian protection by GnRH agonists. CONCLUSION(S): At present, there are no high-level, evidence-based recommendations for preservation of fertility or of ovarian function in women with breast cancer. This is an important issue for young breast cancer survivors, and further studies are needed. Moreover, the interplay between ovarian protection by GnRH agonists and the efficacy of adjuvant chemotherapy remains elusive. Copyright (c) 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.
Authors: Clara González; Marta Devesa; Montserrat Boada; Buenaventura Coroleu; Anna Veiga; Pere N Barri Journal: J Assist Reprod Genet Date: 2011-09-02 Impact factor: 3.412
Authors: Michelle L Matthews; Bradley S Hurst; Paul B Marshburn; Rebecca S Usadi; Margaret A Papadakis; Terry Sarantou Journal: Obstet Gynecol Int Date: 2012-03-18
Authors: Karin Hammarberg; Maggie Kirkman; Catharyn Stern; Robert I McLachlan; Debra Gook; Luk Rombauts; Beverley Vollenhoven; Jane R W Fisher Journal: BMC Health Serv Res Date: 2017-05-10 Impact factor: 2.655
Authors: Ellen Marie Sparidaens; Catharina C M Beerendonk; Kathrin Fleischer; Willianne L D M Nelen; Didi D M Braat; Rosella P M G Hermens Journal: BMC Womens Health Date: 2022-08-03 Impact factor: 2.742